

# A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT06869551

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3
<b>Sponsor</b>	Bristol-Myers Squibb
<b>Enrollment</b>	60 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).
- Participants must have at least three joints that are affected by arthritis.
- Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.

### Exclusion (3)

- Participants must not have been diagnosed with JPsA before 5 years of age.
- Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,
- Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.

## Locations (47 total)

---

Local Institution - 0038, Lancaster, California, United States  
Local Institution - 0020, Chicago, Illinois, United States  
Local Institution - 0023, Indianapolis, Indiana, United States  
... and 44 more locations